This article by Camila Ferezin was originally published on The Green Fund, and appears here with permission.
Innovative Industrial Properties (IIPR) occupies a niche in the cannabis industry, by performing sale-and-leasebacks as a means of providing finances to cannabis companies. Evidently, it s working for them.
Over the past year, shares of the medical cannabis real estate investment trust (REIT)
tenfold its value since December 2016, climbing from USD $18.45 a share to now $194 per share.
IIPR is the only publicly traded marijuana specialty REIT, allowing them to occupy a unique position in the industry.
As marijuana is still illegal at the federal level in the U.S., getting a loan from financial institutions can be an arduous process, if the loan is approved at all. However,
This article by Camila Ferezin was originally published on The Green Fund, and appears here with permission.
Cannabis sativa L. (hemp, marijuana) produces male and female inflorescences on different plants that produce unisexual flowers.
In commercial production, marijuana plants are all genetically feminized, as female plants accumulate far larger amounts of several cannabinoids in the trichomes than male plants, which are often removed or killed. Moreover, the presence of male plants among females often leads to the fecundation of female plants; a fecundated female plant will lead to seed formation, reducing flower quality (as they become hermaphrodites) and buds/cannabinoids yield.
This article by Camila Ferezin was originally published on The Green Fund, and appears here with permission.
As medicinal cannabis products become more accessible in Australia, it becomes increasingly important to know how patients can access some themselves.
The Therapeutic Goods Administration (TGA) announced a final decision to down-schedule certain low dose cannabidiol (CBD) preparations from Schedule 4 (Prescription Medicine) to Schedule 3 (Pharmacist Only Medicine), allowing select medicinal cannabis products to be available over the counter.
The decision will allow TGA approved low-dose CBD containing products, up to a maximum of 150 mg/day, for use in adults, to be supplied over-the-counter by a pharmacist, without a prescription.